Self-taken vaginal swabs versus clinician-taken for detection of candida and bacterial vaginosis: a case-control study in primary care by Barnes P et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Barnes P, Vieira R, Harwood J, Chauhan M.  
Self-taken vaginal swabs versus clinician-taken for detection of candida and 
bacterial vaginosis: a case-control study in primary care.  
British Journal of General Practice 2017, 67(665), e824-e829. 
 
 
Copyright: 
This is the authors’ accepted manuscript of an article that has been published in its final definitive 
form by the Royal College of General Practitioners, 2017. 
 
DOI link to article: 
https://doi.org/10.3399/bjgp17X693629  
Date deposited:   
28/11/2017 
Embargo release date: 
30 November 2018  
02/09/2016  page 1 
 
 
Are self-taken vaginal swabs equivalent to clinician-taken for the detection of candida and 
bacterial vaginosis? 
Authors: P Barnes, R Vieira, J Harwood, M Chauhan 
 
Abstract 
Background: Vaginal discharge and vulvitis are common presenting symptoms in general practice. 
Few studies have specifically looked at the validity of self-taken low vulvovaginal swabs (LVS) for 
the diagnosis of vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV).  
 
Aim: To assess if patient self-taken LVS is a valid alternative to clinician-taken high vaginal swabs 
(HVS) for the detection of VVC and BV. 
 
Design and Setting: Case controlled study with the patient acting as their own control in an urban 
sexual health centre. 
 
Method: Women aged 16-65 years attending with symptomatic vaginal discharge, vulval irritation, 
genital pain and an offensive genital smell were recruited into the study. Participants took a self-
taken LVS prior to vaginal examination, during which a clinician took a HVS (reference standard). 
Main outcome measures were the diagnosis of BV or VVC infection. 
 
Results: A total of 104 women were enrolled. Of those 45 were diagnosed with VVC and 26 with 
BV. The sensitivities of self-taken LVS for VVC and BV were 95.5% and 88.5% respectively. Cohen 
Kappa’s coefficient showed “strong agreement” for the detection of both VVC and BV. Vulval 
itching was the most common symptom associated with VVC (49%), while 65% of women 
diagnosed with BV presented an offensive discharge. Both symptoms had poor positive predictive 
values (0.63 and 0.5, respectively).  
 
Conclusion: Self-taken LVS appears to be a valid alternative to clinician-taken HVS for detecting 
VVC and BV infections. Symptoms were found to be a poor indicator of underlying infection. 
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How this fits in:  
 
For a woman presenting for the first time with a change in vaginal discharge, current guidelines for 
management in General Practice do not generally advocate HVS as a diagnostic tool (1). However a 
number of clinical scenarios do require microbiological confirmation for the diagnosis of abnormal 
discharge (2). We present our finding for the validity of a self-taken vaginal swab in these 
circumstances.  
 
Introduction 
 
Bacterial Vaginosis (BV) is the commonest cause of infective vaginal discharge in women of 
reproductive age (3). Vulvovaginal candidiasis (VVC) is the second most common and particularly 
affects women aged 20 to 30 years (3, 4). Symptomatic vulvovaginal discharge and vulval irritation 
are frequent and often distressing presenting symptoms in women attending both general practice 
surgeries (5) and sexual health services (4, 6). Classical symptoms of VVC are vulval itching 
associated with a thick, white, curdy discharge whilst BV typically presents as a non-irritant, thin, 
grey, offensive discharge (4, 6). However, vaginal symptoms and signs are not a reliable indicator 
of underlying aetiology. BV may cause vulval irritation (7) while VVC may present solely with a 
change in discharge (8). Even women with previously confirmed episodes of VVC are poor at self-
diagnosis (9) and as few as 16% of women with recurrent symptoms typical of candida have VVC 
confirmed on culture (10). Other infective causes of a discharge should always be considered and 
screening is offered for chlamydia, gonorrhoea and trichomonas, particularly in women less than 
25 years of age (2). Non-infective causes for vulval irritation/itching are common (up to half the 
women in one study presenting with symptoms suggestive of VVC were shown to have another 
condition) (4). These include atopy, eczema, lichen sclerosis and vulval carcinoma. In order to make 
a definitive diagnosis, clinicians should ideally perform a genital examination which includes the 
insertion of a speculum and the collection of bacteriological samples for microscopy, culture and 
sensitivity. 
 
In primary care various constraints such as time pressure and lack of a chaperone combined with a 
patient’s reluctance to be examined, can conspire to make a genital inspection with speculum 
examination difficult if not impossible. Clinicians may therefore opt to treat vaginal discharge and 
vulval irritation syndromically without microbiological evidence of infection (5). In cases where 
vulval itching is not in fact due to candidiasis but is triggered by other pathology such as atopy, 
atrophic vaginitis or lichen sclerosis, women may experience symptomatic relief from the 
moisturising action of anti-fungal creams particularly if combined with the anti-inflammatory 
action of hydrocortisone, further muddying the water with regards to diagnosis.  
 
If a high vaginal swab (HVS) is required there is a general consensus in current guidelines that a 
blind swab is acceptable (1, 2). Two large well conducted studies in Leeds in 2014 showed that a 
self-taken low vaginal swab (LVS) is in fact superior to a clinician-taken endocervical swab for the 
detection of chlamydia and gonorrhoea (11,12) and current guidelines have changed to reflect this 
with regards to STI screening (13). There is a reasonable body of research to support the use of a 
self-taken LVS for detection of abnormal vaginal bacteria but very little on the validity of this 
method  for the detection of Candida (14, 15). This study was therefore designed to see if a patient 
self-taken LVS is as reliable as clinician-taken HVS in the diagnosis of both VVC and BV.  
 
Methods 
 
Study population 
 
From May to August 2015, women between 16-65 years of age who presented to The New Croft 
Centre for Sexual Health in Newcastle-upon-Tyne, UK, with symptoms of vaginal discharge, genital 
irritation or offensive genital smell were recruited into the study, after providing informed consent.  
Women already diagnosed with VVC or BV and those with established immunodeficiency, were 
excluded from the trial. No patient was entered more than once.  The study was approved by the 
NHS Research Ethics Committee (REC).  
 
 
Data collection 
 
Those enrolled in the trial were seen by either a doctor or a nurse trained in genito-urinary 
medicine (GUM) and were given both verbal and written instructions on how to perform a LVS. 
They were advised to insert the cotton end of the swab stick 6 cm into the vagina, rotate it for 10 
seconds and then place the swab into Aimes transport medium. The women then underwent a 
speculum examination and a HVS was collected from the posterior fornix by the examining 
clinician. This was also placed into a different Aimes transport medium.  Symptom data was 
collated by summarizing the presenting complaints into 4 categories: vulval irritation/itching, 
offensive discharge, genital pain with abnormal discharge and any other changes to the woman’s 
normal discharge 
 
Laboratory assessment 
 
Both self-taken and physician collected swabs were then sent to the microbiology laboratory for 
microscopy and culture for candida species and organisms causing BV.  For the diagnosis of 
candida, the HVS specimen was cultured on Sabourauds culture medium incubated in air at 35-38 
degrees centigrade for 48hrs and any growing colonies analysed for candida (16). The diagnosis of 
BV was made by gram staining the swab specimens and then using the Hay-Ison scoring 
methodology (17). In addition to swabs being sent for laboratory diagnosis all patients had in-
house wet mount phase microscopy for trichomoniasis and gram staining of specimens looking for 
evidence of candida plus Hay-Ison scoring for BV. Patients with candidiasis were treated with a 
single dose of oral Fluconazole 150mg  those with  BV were given oral Metronidazole 400mg twice 
daily for 7 days .  
 Data analysis 
 
Data was analysed using VassarStats on line statistical computation. Descriptive analyses were 
conducted for all relevant variables and outcomes, using appropriate measures of location (mean or 
median) and dispersion (standard deviation or range) for continuous variables. Categorical variables 
were summarised using absolute frequencies and proportions. The patient self-taken swab 
diagnostic test performance was assessed using the sensitivity, specificity and positive and 
negative predictive values. The Cohen’s Kappa statistic (18) was used to investigate the level of 
agreement between the two test methods.  
 
We followed the interpretation of Cohen’s Kappa suggested by Cohen: values ≤ 0 as indicating no 
agreement, 0.01–0.20 as none to slight, 0.21–0.40 as fair, 0.41– 0.60 as moderate, 0.61–0.80 as 
substantial, and 0.81–1.00 as almost perfect agreement.  When applicable, 95% CI were reported.  
 
Results 
 
Figure 1 summarises the enrolment figures of the patients included in the study, while the 
resulting outcomes of both diagnostic tests for VVC and BV are summarized in Table 1.   
 
The median age of the participants was 26 years old (range 17 – 49).  Out of the 104 women that 
were enrolled during the study period, 97 had complete laboratory data for BV and 99 for VVC. 
(Data was incomplete for 7 patients due to loss of one or both swabs in transit between our 
community based site and the main hospital laboratory.)  
 
Using the clinician HVS as the reference standard, the prevalence of VVC was 45.5% (n=45) while 
the prevalence of BV was 26.8% (n=26). Five women had both VVC and BV and 31 women had 
neither BV nor candida. In addition, eight patients (8.7%) were diagnosed with chlamydia, two 
(2.2%) with chlamydia and gonorrhea and two (2.2%) with herpes.  
  
 
 
Fig. 1. CONSORT chart outlining the study plan and enrolment figures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Summary of the outcome of self-taken LVS and clinician-taken HVS 
 
 
Clinician-taken HVS 
Not detected 
Clinician-taken HVS 
Detected 
Total 
VVC 
Self-taken LVS Not detected 50 2 52 
Self-taken LVS Detected 4 43 47 
Total 54 45 99 
BV 
Self-taken LVS Not detected 68 3 71 
Self-taken LVS Detected 3 23 26 
Total 71 26 97 
 
 
 
 
Eligible patients 
(n=104) 
Patients with lab results for BV  
(n=97) 
Patients with lab results for VVC  
(n=99) 
Excluded patients with missing 
lab results: 
- BV (n=7) 
- VVC (n=5) 
Performance of patient self-taken LVS 
 
For VVC, four patients had a false positive result and two were false negatives, while for BV, three 
resulted in false positives and three in false negatives (Table 1). Using the clinician-taken HVS as 
the reference standard, the sensitivities of self-taken vulvovaginal swabs for BV and VVC were 
88.5% (95% CI 68.7-97.0) and 95.6% (95% CI 83.6-99.2) respectively, as reported in Table 2. 
Specificity of self-taken swab for BV and VVC were 95.8% (CI 87.3-99.0) and 92.6% (CI 81.3-97.6) 
respectively, giving a PPV of 88.5% for BV and 91.5% for VVC.  
 
Table 2. Performance measures for the patient self-taken LVS (clinician-taken HVS as the reference 
standard) 
Infection 
Sensitivity 
% (95%CI) 
Specificity 
% (95%CI) 
PPV 
% 
NPV 
% 
Cohen’s Kappa 
(κ) 
BV 88.5 (68.7-97.0) 95.8 (87.3,99.0) 88.5  95.8 0.84 (0.72,0.96) 
VVC 95.5 (83.6-99.2) 92.6 (81.3,97.6) 91.5 96.2 0.88 (0.78,0.97) 
 
With regards to assessing the level of agreement of the two diagnostic tests for BV, the number of 
observed agreements between clinician-taken HVS and patient taken LVS were 91 (93.81% of the 
observations) and the number of agreements expected by chance were 58.9 (60.76% of the 
observations). Therefore κ = 0.84 for BV which indicates “almost perfect agreement”.  
 
For VVC the number of observed agreements were 93 (93.9%) while the number of agreements 
expected by chance were 49.7 ( 50.2%), which resulted in κ = 0.88 which again indicates “almost 
perfect agreement”.  
 
 
 
Symptom data 
 
Data relating the symptoms presented by the patients are summarized in Table 3.  The commonest 
presenting symptom was offensive discharge (n=38; 39%) followed by vulvo-vaginal itching (n=35; 
36%). A change in normal discharge was present in 21% (n=21) of patients and 3% (n=3) presented 
with genital pain. 
 
 
BV 
(N=21) 
VVC 
(N=40) 
BV and VVC 
(N=5) 
Negative 
(N=31) 
Total 
(N=97) 
Vulval irritation/itching, n (%) 3 (9%) 22 (65%) 2 (6%) 8 (20%) 35 (36%)  
Offensive discharge, n (%) 17 (45%) 6 (16%) 2 (5%) 13 (34%) 38 (39%) 
Genital pain (w/ abnormal 
discharge), n (%) 
0 (0%) 2 (67%) 0 (0%) 1 (33%) 3 (3%) 
Any other changes to normal 
discharge, n (%) 
1 (4%) 10 (48%) 1 (4%) 9 (44%) 21 (21%) 
 
 
Looking at the relation between the symptoms and laboratory diagnosis, using the 97 patients for 
whom we had complete laboratory data for both VVC and BV, of the 35 women who presented 
with vulval itching/irritation 71% were diagnosed with VVC. Of the 38 women who presented with 
an offensive discharge 50% were diagnosed with BV.   
 
With regards to the accuracy of symptoms in the syndromic management of symptomatic vaginal 
discharge, the sensitivity of vulval itching as an indicator of VVC was 0.533 (CI 0.380-0.680), 
specificity was 0.745 (CI 0.607-0.849) giving a positive predictive value (PPV) of 0.631. The 
sensitivity of an offensive discharge as an indicator of BV was 0.73 (CI 0.519-0.876) Specificity was 
0.733 (CI 0.612-0.827) giving a PPV of 0.5. 
 
 
Discussion 
 
Summary: 
 
We found an excellent level of agreement between self-taken and physician collected vaginal 
swabs for the diagnosis of VVC and BV in the study population of women attending our clinic. PPV 
for VVC was 0.915 and 0.885 for BV, showing promising evidence supporting the use of a self-taken 
specimen for the diagnosis of VVC and BV.  
 
Self-taken LVS are by no means a reliable substitute for a thorough genital examination but in a 
time constrained service, combined with patient reluctance to be examined, they appear to have 
similar detection rates to HVS. This swab could be taken in conjunction with self-taken NAATs for 
chlamydia, gonorrhoea and trichomonas thus allowing a number of infections to be investigated 
without the need for a genital examination. This is a particularly attractive screening method for 
adolescent women where up to 80% prefer self-testing to a pelvic examination (19). We therefore 
conclude from this study that self-taken LVS appears to be a valid alternative to clinician-taken HVS 
for detecting VVC and BV infections. 
 
Apart from the very strong agreement between the two swab techniques, an incidental finding 
which is of interest was the apparent invalidity of typical symptoms with regard to directing the 
diagnosis. Vulval irritation as an indicator of VVC showed a poor PPV of 0.63. Equally, offensive 
discharge appeared unreliable for the empirical diagnosis of BV, having a very poor PPV of 0.50. 
This supports other research which has shown that patient perception of their discharge is not a 
reliable indicator of likely pathology (9).  
 
Strengths and Weaknesses: 
 
Although the sample size of our study is relatively small, the 95% CI for Cohen’s kappa indicates 
that we are confident that the level of agreement between the two testing methods is at least 
substantial (minimum κ =0.72 for BV and minimum κ = 0.78 for VVC).Therefore we surmise that a 
further extension of the study would show similar results. 
 
A limitation of this study is  that although we tested for trichomoniasis using in-house wet mount 
microscopy, (the laboratory also used a wet mount screening test) we did not use a nucleic acid 
amplification test (NAAT) which is more reliable (wet mount sensitivity 45-60% as opposed to 
NAAT sensitivity 98-99%) (20). We have a low incidence of trichomoniasis in our service of <1% but 
it is possible that undiagnosed trichomoniasis may have impacted on the figures for symptom 
correlation with microbiological findings  
 
Another limitation of our study was that the laboratory staff who analysed the swabs were not 
blinded as to whether the swab was self-collected or physician collected. However we do not think 
this would have impacted significantly upon the data. All swabs were cultured using the same 
media and analysed in a way which was unlikely to have been biased.  
 
 
Comparison with Existing Literature: 
 
Self-taken LVS have been shown in numerous studies to be accurate for the detection of 
chlamydia, gonorrhoea, and trichomoniasis. Two notable studies conducted in Leeds General 
Infirmary, showed that self-taken LVS are superior to clinician-taken endocervical swabs for NAAT 
detection of chlamydia and gonorrhoea (11, 12). A number of studies have also shown self-taken 
LVS are highly acceptable to patients (21, 22) and are extremely cost effective (23). There are 
however only a few studies comparing the accuracy of self-taken LVS to clinician-taken HVS for the 
detection of BV (14,15) and a particular paucity of evidence supporting self-taken LVS for the 
diagnosis of VVC. 
 
Implications for Research and/or Practice: 
 
In general practice HVS has a place in the first line management of a number of specific clinical 
scenarios (see text box). In the management of an uncomplicated first presentation of abnormal 
vaginal discharge it is however of debatable use particularly in the diagnosis of BV (2, 3). The flora 
typical of BV can be found in up to 40% of asymptomatic women in the UK (6) while Candida 
Albicans is an asymptomatic commensal in 10-20% of women (4). Recommended guidelines for the 
initial management of abnormal vaginal discharge in primary care rely on a combination of detailed 
clinical story with an examination which includes the use of PH paper and not necessarily the 
collection of a HVS (21).  
 
There are a number of clinical scenarios when an HVS is recommended (2). HVS should be part of 
the management plan in recurrent candidiasis, screening for group B strep infections, post-partum 
and post instrumentation infections, vaginitis without discharge, symptoms not characteristic of BV 
or VVC, previous treatment failure and recurrent vaginal discharge (>= 4 cases year). In these 
instances if vaginal examination for whatever reason is deferred our study suggests that self-taken 
LVS may be as useful in assisting the diagnosis as clinician-taken HVS.   
 
In the light of the finding of this study we would also suggest that in first presentation of cases 
suggestive of VVC, a LVS, particularly if it were to be negative, would be helpful in directing the 
diagnosis. 
 
With regards to trichomonas (TV), infection with this sexually transmitted and may present with 
symptoms suggestive of BV thereby creating the potential for misdiagnosis (24). Although the 
treatment for TV is the same as for BV (400mg metronidazole BD for 7 days) TV being an STI 
requires partner notification. Although our regional rate for TV is low, it is significantly higher in 
other areas such as London and the West Midlands (25). Interpretation of our study findings should 
therefore be made with consideration of local rates for TV. In women presenting with recurrent 
symptoms suggestive of BV trichomonas should be excluded. 
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